The c-peptide test measures the level of c-peptide in blood, a direct marker of how much insulin your pancreas is making on its own. Fasting normal is roughly 0.5 to 2.0 ng/mL, random non-fasting runs 0.8 to 3.5 ng/mL, and stimulated values after a mixed meal are higher. The test is most useful for telling apart type 1 diabetes (typically low), type 2 diabetes (normal or high), and LADA (intermediate, falling over time), and for assessing beta-cell reserve in established diabetes.
What C-Peptide Is and Why It Matters
When beta cells make insulin, they first make a single precursor molecule called proinsulin. Inside the secretory granule, proinsulin is cleaved into two pieces — insulin and c-peptide (“connecting peptide”) — and both are released into the bloodstream in a 1:1 molar ratio.
Because the pancreas releases exactly one c-peptide for every insulin molecule, measuring c-peptide is a direct measure of endogenous insulin production. Three properties make c-peptide more useful than measuring insulin directly:
- Longer half-life: c-peptide lasts about 30 minutes in circulation, versus 5 minutes for insulin. This makes c-peptide levels more stable and easier to interpret on a single blood draw.
- No first-pass clearance: insulin is mostly cleared by the liver on first pass, but c-peptide is cleared by the kidneys at a steady rate.
- Distinguishes endogenous from injected insulin: injected insulin does not contain c-peptide. Someone on insulin therapy or who has injected insulin surreptitiously will have measurable insulin but low or zero c-peptide.
Reference Ranges
| State | Typical c-peptide range | Notes |
|---|---|---|
| Fasting (8h) | 0.5 to 2.0 ng/mL | Most common test; some labs use nmol/L (0.17 to 0.66) |
| Random non-fasting | 0.8 to 3.5 ng/mL | Higher because of recent meal-stimulated secretion |
| Post mixed-meal (90 min) | 1.5 to 5.0 ng/mL | Peak after standardized meal challenge |
| Post-glucagon (6 min) | 1.5 to 4.0 ng/mL | Used in research and transplant evaluation |
| Type 1 diabetes (established) | Less than 0.6 ng/mL | Often undetectable in long-standing T1D |
| Type 2 diabetes (typical) | 1.0 to 4.0 ng/mL | Normal or elevated, especially in insulin resistance |
| LADA | 0.6 to 1.5 ng/mL, declining | Intermediate; falls over years |
| Insulinoma | Greater than 0.6 with hypoglycemia | Inappropriate c-peptide during low glucose |
Reference ranges vary by laboratory and assay. Always interpret c-peptide alongside the simultaneous glucose, because a “normal” c-peptide can mean very different things depending on whether blood sugar is 60 or 300.
When the C-Peptide Test Is Ordered
| Clinical question | Why c-peptide helps |
|---|---|
| Is this T1D or T2D? | Low c-peptide with hyperglycemia points to T1D; normal/high to T2D |
| Is this LADA? | Adult-onset diabetes with intermediate c-peptide plus positive GAD-65 autoantibody |
| Can this person stop insulin? | If c-peptide is preserved (greater than 1.0 ng/mL), some patients can transition off insulin |
| Insulin pump candidacy | Some Medicare rules use c-peptide thresholds for pump coverage |
| Hypoglycemia workup | Distinguishes insulinoma (high c-peptide) from injected insulin (low c-peptide) |
| Pre-transplant assessment | Establishes residual beta-cell function before pancreas or islet transplant |
| MODY suspicion | Preserved c-peptide years into diabetes raises monogenic diabetes possibility |
How the Test Is Performed
The basic version is a simple blood draw — typically after an 8-hour overnight fast, with a simultaneous fasting glucose. The c-peptide level is interpreted in the context of that glucose: a c-peptide of 1.0 ng/mL means different things if glucose is 90 versus 250.
For more detailed beta-cell assessment, two stimulation tests exist:
- Mixed-meal tolerance test (MMTT): baseline blood draw, then a standardized liquid meal (Boost or Sustacal), then sequential c-peptide draws at 30, 60, 90, 120 minutes. Area under the curve (AUC) is the primary measure. The MMTT is the gold standard in type 1 diabetes clinical trials and TrialNet studies.
- Glucagon stimulation test: baseline draw, then 1 mg IV glucagon, then c-peptide at 6 minutes. Faster than MMTT but causes nausea in many patients.
Interpreting C-Peptide in Diabetes Classification
| Pattern | Likely diagnosis | Implication |
|---|---|---|
| Low c-peptide + high glucose + positive autoantibodies | Type 1 diabetes | Insulin-dependent; intensive insulin therapy needed |
| Normal/high c-peptide + high glucose + negative autoantibodies | Type 2 diabetes | Lifestyle, metformin, GLP-1, may not need insulin |
| Intermediate c-peptide + adult onset + GAD-65 positive | LADA (slow-onset T1D) | May start oral agents; will need insulin within years |
| Preserved c-peptide + young onset + family history | Consider MODY | Genetic testing; some forms respond to sulfonylureas |
| Low c-peptide + low glucose + low insulin | Adrenal insufficiency, malnutrition, sepsis | Look beyond diabetes |
| Low c-peptide + low glucose + high insulin | Exogenous insulin (factitious or accidental) | Investigate insulin source |
| High c-peptide + low glucose (in fasting state) | Insulinoma or nesidioblastosis | Imaging and surgical workup |
Sensitivity, Specificity, and Limitations
- Sensitivity for T1D: A fasting c-peptide less than 0.6 ng/mL (or stimulated less than 0.2 nmol/L) has greater than 90 percent sensitivity for established T1D.
- Overlap zone: values between 0.6 and 1.5 ng/mL are ambiguous — combine with autoantibody testing for classification.
- Honeymoon phase: newly diagnosed T1D may have transiently preserved c-peptide for 6 to 18 months (the “honeymoon period”).
- Renal interference: chronic kidney disease impairs c-peptide clearance and falsely elevates the level. A patient with ESRD may have a c-peptide of 5 ng/mL despite poor beta-cell function. Use the c-peptide-to-glucose ratio or stimulated testing in CKD.
- Glucose context required: always pair with simultaneous glucose. A c-peptide of 1.5 ng/mL with glucose of 350 mg/dL is inappropriately low.
- Assay variability: commercial c-peptide assays are reasonably standardized but not perfectly interchangeable across labs.
C-Peptide and Insulin Therapy Decisions
One practical use of c-peptide is helping decide whether someone with diabetes on insulin can come off it. In general:
- Fasting c-peptide greater than 1.0 ng/mL and stimulated greater than 1.8 ng/mL: often suggests beta-cell reserve adequate to manage on non-insulin therapy if A1C is acceptable
- Fasting c-peptide 0.6 to 1.0 ng/mL: intermediate; may need insulin at meals or basal coverage
- Fasting c-peptide less than 0.6 ng/mL: insulin dependence is highly likely
These thresholds are guidelines, not rules. Real-world decisions weigh glucose patterns, A1C, hypoglycemia history, and patient preference. Talk to your endocrinologist before changing insulin therapy.
C-Peptide in Hypoglycemia Workup
The single most important reason to draw a c-peptide outside diabetes classification is the workup of unexplained hypoglycemia. The pattern is:
- Insulinoma: low glucose + high insulin + high c-peptide (endogenous source). Proinsulin is also elevated.
- Factitious hypoglycemia (surreptitious insulin): low glucose + high insulin + low or undetectable c-peptide (exogenous source).
- Sulfonylurea ingestion: low glucose + high insulin + high c-peptide. Toxicology screen will detect the drug.
- Non-islet cell tumor hypoglycemia: low glucose + low insulin + low c-peptide (IGF-2 mediated).
Related Reading
See our broader guides on detection of prediabetes, fasting insulin testing, HOMA-IR, and GAD-65 autoantibodies for the related diagnostic tests used alongside c-peptide.
The Bottom Line
The c-peptide test is a versatile measure of endogenous insulin production with a fasting reference range of roughly 0.5 to 2.0 ng/mL. Its main clinical role is helping classify diabetes — low values point toward type 1 or advanced beta-cell failure, normal-to-high values point toward type 2 or insulin resistance, and intermediate values warrant autoantibody testing for LADA. It is also essential in hypoglycemia workup for telling endogenous insulin secretion from injected insulin. Always interpret c-peptide alongside the simultaneous glucose and remember that renal failure can falsely elevate the value. Talk to your endocrinologist about whether c-peptide testing makes sense for your situation.
